TAVR塞栓保護の世界市場：製品別：機会分析と産業予測（2023年～2032年）

世界のTAVR塞栓保護の市場規模は、2022年に1億878万2,530米ドルに達し、2023年～2032年にCAGR14％を記録し、2032年には4億544万670米ドルに達すると予測されています。

経カテーテル大動脈弁置換術（TAVR）の塞栓保護装置は、TAVR手術中に使用される特殊な医療機器です。

TAVRは、心臓の大動脈弁が狭くなって血流を阻害する状態である大動脈弁狭窄症を治療するために考案された低侵襲手術法です。TAVRでは通常、新しい人工弁がカテーテルを介して心臓に挿入されるため、開心術の必要性が回避されます。

TAVR手術で使用される塞栓保護装置は、手術中に脱落する可能性のある塞栓屑（小さな粒子や血栓）を捕捉し、放出を防止するよう特別に設計されています。これらの塞栓屑は血流にのって移動し、脳を含む他の臓器の閉塞や損傷を引き起こす可能性があり、脳卒中や臓器損傷などの合併症を引き起こす可能性があります。

TAVR塞栓保護装置の主な機能は、弁置換術中に外れる可能性のある破片を捕捉して封じ込めることにより、塞栓のリスクを軽減することです。これらの装置は、血管内に挿入され、塞栓物質が害を及ぼす前に捕捉するフィルターやメッシュ状の構造で構成されていることが多くあります。TAVR塞栓保護市場の成長は、主に心血管疾患、特に大動脈弁狭窄症の罹患率の上昇と高齢者人口の拡大によって促進されています。

例えば、2021年にNational Library of Medicineに掲載された論文によると、大動脈弁狭窄症（AVS）は一般的な心臓弁膜症で、加齢とともに有病率が高くなり、75歳以上の患者の約13.2％が罹患しています。この疾患は、弁尖の瘢痕化とカルシウムの蓄積を特徴とします。

TAVRのような低侵襲手術を選択することが多い高齢者層における大動脈弁狭窄症の有病率の増加は、脳塞栓保護装置の需要を促進する重要な要因です。これらの装置は、TAVR手術中の塞栓破片の脱落に関連する合併症を最小限に抑えるために不可欠です。そのため、心血管疾患に罹患しやすい高齢者の間で、大動脈弁狭窄症の治療選択肢としてTAVRを選好する傾向が高まっていることが、脳塞栓保護装置の需要を煽り、市場の成長を促しています。

しかし、市場成長を抑制する要因として、手術の複雑さや高額なTAVR塞栓保護が挙げられます。これらの装置の使用には、医療専門家向けの専門的なトレーニングが必要な場合が多く、導入の課題となっています。加えて、脳塞栓保護装置関連の高コストは、特に医療予算が限られている地域では大きな抑止力になり得ます。

そのため、医療従事者や患者にとって塞栓保護装置がより身近な存在となるよう、手術の簡素化やコスト削減に取り組む必要があります。さらに、先進医療機器の開発における政府機関や主要業界企業による取り組みが増加していることから、市場は潜在的な成長を遂げる可能性を秘めています。こうした協力的な取り組みは、脳塞栓保護装置の安全性と有効性を高めることを目的としており、患者の予後改善につながる可能性があります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

• 市場の定義と範囲
• 主な調査結果
  • 影響要因
  • 主な投資機会
• ポーターのファイブフォース分析
• 市場力学
  • 促進要因
    • 死亡率の低下
    • TAVR塞栓保護装置の技術的進歩
    • 低侵襲手術の採用拡大
  • 抑制要因
    • 製品の不具合とリコール
    • 手術の複雑さ
  • 機会
    • 研究開発への注目の高まり

第4章 TAVR塞栓保護市場：製品別

• 概要
• SENTINEL脳保護システム
• TriGUARD 3 CEP装置技術

第5章 TAVR塞栓保護市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • その他
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • その他
• ラテンアメリカ・中東・アフリカ
  • ラテンアメリカ
  • 中東・アフリカ

第6章 競合情勢

• イントロダクション
• 主要成功戦略
• 主要10社の製品マッピング
• 競合ダッシュボード
• 競合ヒートマップ
• 主要企業のポジショニング（2022年）

第7章 企業プロファイル

• Boston Scientific Corporation
• Edward Lifesciences Corporation
• Filterlex Medical Ltd.
• Protembis GmbH
• Innovative Cardiovascular Solutions, LLC.
• EnCompass Technologies, Inc.
• Transverse Medical Inc.
• Emboline, Inc.
• Cardioptimus
• Venus MedTech HangZhou Inc.

LIST OF TABLES

• TABLE 01. GLOBAL TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 02. TAVR EMBOLIC PROTECTION MARKET FOR SENTINEL CEREBRAL PROTECTION SYSTEM, BY REGION, 2022-2032 ($THOUSAND)
• TABLE 03. TAVR EMBOLIC PROTECTION MARKET FOR TRIGUARD 3 CEP DEVICE TECHNOLOGY, BY REGION, 2022-2032 ($THOUSAND)
• TABLE 04. TAVR EMBOLIC PROTECTION MARKET, BY REGION, 2022-2032 ($THOUSAND)
• TABLE 05. NORTH AMERICA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 06. NORTH AMERICA TAVR EMBOLIC PROTECTION MARKET, BY COUNTRY, 2022-2032 ($THOUSAND)
• TABLE 07. U.S. TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 08. CANADA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 09. EUROPE TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 10. EUROPE TAVR EMBOLIC PROTECTION MARKET, BY COUNTRY, 2022-2032 ($THOUSAND)
• TABLE 11. GERMANY TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 12. FRANCE TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 13. UK TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 14. ITALY TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 15. REST OF EUROPE TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 16. ASIA-PACIFIC TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 17. ASIA-PACIFIC TAVR EMBOLIC PROTECTION MARKET, BY COUNTRY, 2022-2032 ($THOUSAND)
• TABLE 18. JAPAN TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 19. CHINA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 20. INDIA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 21. AUSTRALIA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 22. REST OF ASIA-PACIFIC TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 23. LAMEA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 24. LAMEA TAVR EMBOLIC PROTECTION MARKET, BY COUNTRY, 2022-2032 ($THOUSAND)
• TABLE 25. LATIN AMERICA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 26. MIDDLE EAST AND AFRICA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
• TABLE 27. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
• TABLE 28. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
• TABLE 29. BOSTON SCIENTIFIC CORPORATION: PRODUCT SEGMENTS
• TABLE 30. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
• TABLE 31. EDWARD LIFESCIENCES CORPORATION: KEY EXECUTIVES
• TABLE 32. EDWARD LIFESCIENCES CORPORATION: COMPANY SNAPSHOT
• TABLE 33. EDWARD LIFESCIENCES CORPORATION: PRODUCT SEGMENTS
• TABLE 34. EDWARD LIFESCIENCES CORPORATION: PRODUCT PORTFOLIO
• TABLE 35. FILTERLEX MEDICAL LTD.: KEY EXECUTIVES
• TABLE 36. FILTERLEX MEDICAL LTD.: COMPANY SNAPSHOT
• TABLE 37. FILTERLEX MEDICAL LTD.: PRODUCT SEGMENTS
• TABLE 38. FILTERLEX MEDICAL LTD.: PRODUCT PORTFOLIO
• TABLE 39. FILTERLEX MEDICAL LTD.: KEY STRATERGIES
• TABLE 40. PROTEMBIS GMBH: KEY EXECUTIVES
• TABLE 41. PROTEMBIS GMBH: COMPANY SNAPSHOT
• TABLE 42. PROTEMBIS GMBH: PRODUCT SEGMENTS
• TABLE 43. PROTEMBIS GMBH: PRODUCT PORTFOLIO
• TABLE 44. PROTEMBIS GMBH: KEY STRATERGIES
• TABLE 45. INNOVATIVE CARDIOVASCULAR SOLUTIONS, LLC.: KEY EXECUTIVES
• TABLE 46. INNOVATIVE CARDIOVASCULAR SOLUTIONS, LLC.: COMPANY SNAPSHOT
• TABLE 47. INNOVATIVE CARDIOVASCULAR SOLUTIONS, LLC.: PRODUCT SEGMENTS
• TABLE 48. INNOVATIVE CARDIOVASCULAR SOLUTIONS, LLC.: PRODUCT PORTFOLIO
• TABLE 49. ENCOMPASS TECHNOLOGIES, INC.: KEY EXECUTIVES
• TABLE 50. ENCOMPASS TECHNOLOGIES, INC.: COMPANY SNAPSHOT
• TABLE 51. ENCOMPASS TECHNOLOGIES, INC.: PRODUCT SEGMENTS
• TABLE 52. ENCOMPASS TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
• TABLE 53. ENCOMPASS TECHNOLOGIES, INC.: KEY STRATERGIES
• TABLE 54. TRANSVERSE MEDICAL INC.: KEY EXECUTIVES
• TABLE 55. TRANSVERSE MEDICAL INC.: COMPANY SNAPSHOT
• TABLE 56. TRANSVERSE MEDICAL INC.: PRODUCT SEGMENTS
• TABLE 57. TRANSVERSE MEDICAL INC.: PRODUCT PORTFOLIO
• TABLE 58. EMBOLINE, INC.: KEY EXECUTIVES
• TABLE 59. EMBOLINE, INC.: COMPANY SNAPSHOT
• TABLE 60. EMBOLINE, INC.: PRODUCT SEGMENTS
• TABLE 61. EMBOLINE, INC.: PRODUCT PORTFOLIO
• TABLE 62. EMBOLINE, INC.: KEY STRATERGIES
• TABLE 63. CARDIOPTIMUS: KEY EXECUTIVES
• TABLE 64. CARDIOPTIMUS: COMPANY SNAPSHOT
• TABLE 65. CARDIOPTIMUS: PRODUCT SEGMENTS
• TABLE 66. CARDIOPTIMUS: PRODUCT PORTFOLIO
• TABLE 67. VENUS MEDTECH HANGZHOU INC.: KEY EXECUTIVES
• TABLE 68. VENUS MEDTECH HANGZHOU INC.: COMPANY SNAPSHOT
• TABLE 69. VENUS MEDTECH HANGZHOU INC.: PRODUCT SEGMENTS
• TABLE 70. VENUS MEDTECH HANGZHOU INC.: PRODUCT PORTFOLIO
• TABLE 71. VENUS MEDTECH HANGZHOU INC.: KEY STRATERGIES

LIST OF FIGURES

• FIGURE 01. TAVR EMBOLIC PROTECTION MARKET, 2022-2032
• FIGURE 02. SEGMENTATION OF TAVR EMBOLIC PROTECTION MARKET,2022-2032
• FIGURE 03. TOP IMPACTING FACTORS IN TAVR EMBOLIC PROTECTION MARKET (2022 TO 2032)
• FIGURE 04. TOP INVESTMENT POCKETS IN TAVR EMBOLIC PROTECTION MARKET (2023-2032)
• FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
• FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
• FIGURE 07. MODERATE THREAT OF SUBSTITUTES
• FIGURE 08. MODERATE INTENSITY OF RIVALRY
• FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
• FIGURE 10. GLOBAL TAVR EMBOLIC PROTECTION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
• FIGURE 11. TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022 AND 2032(%)
• FIGURE 12. COMPARATIVE SHARE ANALYSIS OF TAVR EMBOLIC PROTECTION MARKET FOR SENTINEL CEREBRAL PROTECTION SYSTEM, BY COUNTRY 2022 AND 2032(%)
• FIGURE 13. COMPARATIVE SHARE ANALYSIS OF TAVR EMBOLIC PROTECTION MARKET FOR TRIGUARD 3 CEP DEVICE TECHNOLOGY, BY COUNTRY 2022 AND 2032(%)
• FIGURE 14. TAVR EMBOLIC PROTECTION MARKET BY REGION, 2022 AND 2032(%)
• FIGURE 15. U.S. TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 16. CANADA TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 17. GERMANY TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 18. FRANCE TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 19. UK TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 20. ITALY TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 21. REST OF EUROPE TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 22. JAPAN TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 23. CHINA TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 24. INDIA TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 25. AUSTRALIA TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 26. REST OF ASIA-PACIFIC TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 27. LATIN AMERICA TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 28. MIDDLE EAST AND AFRICA TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
• FIGURE 29. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
• FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
• FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
• FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 33. COMPETITIVE DASHBOARD
• FIGURE 34. COMPETITIVE HEATMAP: TAVR EMBOLIC PROTECTION MARKET
• FIGURE 35. TOP PLAYER POSITIONING, 2022
• FIGURE 36. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2020-2022 ($MILLION)
• FIGURE 37. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 38. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 39. EDWARD LIFESCIENCES CORPORATION: NET SALES, 2020-2022 ($MILLION)
• FIGURE 40. EDWARD LIFESCIENCES CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 41. EDWARD LIFESCIENCES CORPORATION: REVENUE SHARE BY REGION, 2022 (%)

The TAVR embolic protection market was valued for $108,782.53 thousand in 2022 and is estimated to reach $405,440.67 thousand by 2032, exhibiting a CAGR of 14% from 2023 to 2032.

Transcatheter aortic valve replacement (TAVR) embolic protection devices are specialized medical devices used during TAVR procedures. TAVR is a minimally invasive surgical technique designed to treat aortic valve stenosis, a condition in which the aortic valve in the heart becomes narrowed and obstructs blood flow. During TAVR, a new artificial valve is typically inserted into the heart through a catheter, avoiding the need for open-heart surgery.

Embolic protection devices used in TAVR procedures are specifically designed to capture and prevent the release of embolic debris (small particles or clots) that may break loose during the procedure. These embolic debris can potentially travel through the bloodstream and cause blockages or damage to other organs, including the brain, which can lead to complications such as stroke or organ damage.

The primary function of TAVR embolic protection devices is to reduce the risk of embolic events by capturing and containing any debris that might dislodge during the valve replacement procedure. These devices often consist of filters or mesh-like structures that are inserted into blood vessels to catch and trap any embolic material before it can cause harm. The growth of the TAVR embolic protection market is primarily driven by rise in incidence of cardiovascular diseases, particularly aortic valve stenosis, and the expanding geriatric population.

For instance, according to an article published in the National Library of Medicine, in 2021, aortic valve stenosis (AVS) is a common heart valve condition that becomes more prevalent with age, affecting approximately 13.2% of patients aged 75 and older. This condition is characterized by the scarring and accumulation of calcium in the valve cusp.

The growing prevalence of aortic valve stenosis in the elderly population, who often choose minimally invasive procedures such as TAVR, is a key factor driving the demand for cerebral embolic protection devices. These devices are essential for minimizing complications associated with the dislodgment of embolic debris during TAVR procedures. Thus, rise in preference for TAVR as a treatment option for aortic valve stenosis among elderly patients, who are more susceptible to cardiovascular diseases, fuels the demand for cerebral embolic protection devices and thereby drives the market growth.

However, factors that hamper the market growth include procedural complexities and high costs TAVR embolic protection devices. Utilization of these devices often requires specialized training for healthcare professionals, contributing to the challenge of implementation. In addition, the high cost associated with cerebral embolic protection devices can be a significant deterrent, particularly in regions with limited healthcare budgets.

Thus, the combination of these factors can hinder widespread adoption and market growth, necessitating efforts to simplify procedures and reduce costs to make these devices more accessible to healthcare providers and patients. Furthermore, the market is poised for potential growth, owing to a rise in initiatives undertaken by government organizations and key industry players in the development of advanced devices. These collaborative efforts aim to enhance the safety and effectiveness of cerebral embolic protection devices, which can lead to better patient outcomes.

In addition, ongoing clinical trials focused on improving these devices are expected to yield promising results. These developments are anticipated to create lucrative opportunities for the market expansion during the forecast period, as they can lead to the introduction of more innovative and efficient cerebral embolic protection solutions, meeting the evolving needs of healthcare providers and patients.

The TAVR embolic protection market is segmented into product type and region. By product type, the market is categorized into SENTINEL cerebral protection system and TriGUARD 3 CEP device technology. Region-wise, the market is analyzed across North America (the U.S. and Canada), Europe (Germany, France, the UK, Italy, and rest of Europe), Asia-Pacific (Japan, China, Australia, India and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).

The key players operating in the TAVR embolic protection market are Boston Scientific Corporation, Edward Lifesciences Corporation, Filterlex Medical Ltd., Innovative Cardiovascular Solutions, LLC., Protembis GmbH, Transverse Medical Inc., Emboline, Inc., Cardioptimus ,EnCompass Technologies, Inc., and Venus MedTech HangZhou Inc. The key players have adopted strategies such as product approval, funding and clinical trials to enhance their product portfolio.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tavr embolic protection market analysis from 2022 to 2032 to identify the prevailing tavr embolic protection market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the tavr embolic protection market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global tavr embolic protection market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Additional company profiles with specific to client's interest
• Expanded list for Company Profiles
• Historic market data

Key Market Segments

By Product

• SENTINEL cerebral protection system
• TriGUARD 3 CEP device technology

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Latin America
  • Middle East And Africa

Key Market Players:

• Protembis GmbH
• Innovative Cardiovascular Solutions, LLC.
• Filterlex Medical Ltd.
• Cardioptimus
• Transverse Medical Inc.
• Venus MedTech HangZhou Inc.
• EnCompass Technologies, Inc.
• Boston Scientific Corporation
• Edward Lifesciences Corporation
• Emboline, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Reduced mortality rate
    • 3.4.1.2. Technological advancements in TAVR embolic protection devices
    • 3.4.1.3. Growing adoption of minimally invasive procedures
  • 3.4.2. Restraints
    • 3.4.2.1. Product failure and recalls
    • 3.4.2.2. Procedural Complexity
  • 3.4.3. Opportunities
    • 3.4.3.1. Growing focus on Research and development

CHAPTER 4: TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. SENTINEL cerebral protection system
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. TriGUARD 3 CEP device technology
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country

CHAPTER 5: TAVR EMBOLIC PROTECTION MARKET, BY REGION

• 5.1. Overview
  • 5.1.1. Market size and forecast By Region
• 5.2. North America
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by Product
  • 5.2.3. Market size and forecast, by country
    • 5.2.3.1. U.S.
    • 5.2.3.1.1. Market size and forecast, by Product
    • 5.2.3.2. Canada
    • 5.2.3.2.1. Market size and forecast, by Product
• 5.3. Europe
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by Product
  • 5.3.3. Market size and forecast, by country
    • 5.3.3.1. Germany
    • 5.3.3.1.1. Market size and forecast, by Product
    • 5.3.3.2. France
    • 5.3.3.2.1. Market size and forecast, by Product
    • 5.3.3.3. UK
    • 5.3.3.3.1. Market size and forecast, by Product
    • 5.3.3.4. Italy
    • 5.3.3.4.1. Market size and forecast, by Product
    • 5.3.3.5. Rest of Europe
    • 5.3.3.5.1. Market size and forecast, by Product
• 5.4. Asia-Pacific
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by Product
  • 5.4.3. Market size and forecast, by country
    • 5.4.3.1. Japan
    • 5.4.3.1.1. Market size and forecast, by Product
    • 5.4.3.2. China
    • 5.4.3.2.1. Market size and forecast, by Product
    • 5.4.3.3. India
    • 5.4.3.3.1. Market size and forecast, by Product
    • 5.4.3.4. Australia
    • 5.4.3.4.1. Market size and forecast, by Product
    • 5.4.3.5. Rest of Asia-Pacific
    • 5.4.3.5.1. Market size and forecast, by Product
• 5.5. LAMEA
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by Product
  • 5.5.3. Market size and forecast, by country
    • 5.5.3.1. Latin America
    • 5.5.3.1.1. Market size and forecast, by Product
    • 5.5.3.2. Middle East And Africa
    • 5.5.3.2.1. Market size and forecast, by Product

CHAPTER 6: COMPETITIVE LANDSCAPE

• 6.1. Introduction
• 6.2. Top winning strategies
• 6.3. Product mapping of top 10 player
• 6.4. Competitive dashboard
• 6.5. Competitive heatmap
• 6.6. Top player positioning, 2022

CHAPTER 7: COMPANY PROFILES

• 7.1. Boston Scientific Corporation
  • 7.1.1. Company overview
  • 7.1.2. Key executives
  • 7.1.3. Company snapshot
  • 7.1.4. Operating business segments
  • 7.1.5. Product portfolio
  • 7.1.6. Business performance
• 7.2. Edward Lifesciences Corporation
  • 7.2.1. Company overview
  • 7.2.2. Key executives
  • 7.2.3. Company snapshot
  • 7.2.4. Operating business segments
  • 7.2.5. Product portfolio
  • 7.2.6. Business performance
• 7.3. Filterlex Medical Ltd.
  • 7.3.1. Company overview
  • 7.3.2. Key executives
  • 7.3.3. Company snapshot
  • 7.3.4. Operating business segments
  • 7.3.5. Product portfolio
  • 7.3.6. Key strategic moves and developments
• 7.4. Protembis GmbH
  • 7.4.1. Company overview
  • 7.4.2. Key executives
  • 7.4.3. Company snapshot
  • 7.4.4. Operating business segments
  • 7.4.5. Product portfolio
  • 7.4.6. Key strategic moves and developments
• 7.5. Innovative Cardiovascular Solutions, LLC.
  • 7.5.1. Company overview
  • 7.5.2. Key executives
  • 7.5.3. Company snapshot
  • 7.5.4. Operating business segments
  • 7.5.5. Product portfolio
• 7.6. EnCompass Technologies, Inc.
  • 7.6.1. Company overview
  • 7.6.2. Key executives
  • 7.6.3. Company snapshot
  • 7.6.4. Operating business segments
  • 7.6.5. Product portfolio
  • 7.6.6. Key strategic moves and developments
• 7.7. Transverse Medical Inc.
  • 7.7.1. Company overview
  • 7.7.2. Key executives
  • 7.7.3. Company snapshot
  • 7.7.4. Operating business segments
  • 7.7.5. Product portfolio
• 7.8. Emboline, Inc.
  • 7.8.1. Company overview
  • 7.8.2. Key executives
  • 7.8.3. Company snapshot
  • 7.8.4. Operating business segments
  • 7.8.5. Product portfolio
  • 7.8.6. Key strategic moves and developments
• 7.9. Cardioptimus
  • 7.9.1. Company overview
  • 7.9.2. Key executives
  • 7.9.3. Company snapshot
  • 7.9.4. Operating business segments
  • 7.9.5. Product portfolio
• 7.10. Venus MedTech HangZhou Inc.
  • 7.10.1. Company overview
  • 7.10.2. Key executives
  • 7.10.3. Company snapshot
  • 7.10.4. Operating business segments
  • 7.10.5. Product portfolio
  • 7.10.6. Key strategic moves and developments